About Topas Therapeutics
Topas Therapeutics is a company based in Hamburg (Germany) founded in 2016. Topas Therapeutics has raised $67.46 million across 6 funding rounds from investors including Evotec, Gimv and European Union. The company has 14 employees as of December 31, 2020. Topas Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Hamburg, Germany
- Employees 14 as on 31 Dec, 2020
-
Sectors
TechnologyHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$67.46 M (USD)
in 6 rounds
-
Latest Funding Round
$21.27 M (USD), Series B
Jul 29, 2021
-
Investors
Evotec
& 7 more
-
Employee Count
14
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Topas Therapeutics
Unlock access to complete
Funding Insights of Topas Therapeutics
Topas Therapeutics has successfully raised a total of $67.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $21.27 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $21.3M
-
First Round
First Round
(22 Mar 2016)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series B - Topas Therapeutics | Valuation |
investors |
|
| Mar, 2021 | Amount | Grant - Topas Therapeutics | Valuation |
investors |
|
| Oct, 2020 | Amount | Series B - Topas Therapeutics | Valuation | Vesalius Biocapital III , BioMedPartners |
|
Investors in Topas Therapeutics
Topas Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, Gimv and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A European life sciences venture capital investor is operated.
|
Founded Year | Domain | Location | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Topas Therapeutics
Financial Statements - Topas Therapeutics
Topas Therapeutics Comparisons
Competitors of Topas Therapeutics
Topas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Frequently Asked Questions about Topas Therapeutics
Topas Therapeutics was founded in 2016.
Topas Therapeutics is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Topas Therapeutics is a funded company, having raised a total of $67.46M across 6 funding rounds to date. The company's 1st funding round was a Series B of $25.77M, raised on Mar 22, 2016.
As of Dec 31, 2020, the latest employee count at Topas Therapeutics is 14.
Founded in 2016 and based in Hamburg, Germany, nanoparticle-based therapeutics targeting immunology disorders are developed. Operations focus on the biotech sector, with a pipeline that includes TPM 203 for pemphigus vulgaris, TPM 501502 for celiac disease, and interventions for anti-drug immune responses. Research and development activities are centered on advancing these candidates toward clinical applications in immune-related conditions.
Topas Therapeutics's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Topas Therapeutics has 8 investors. Key investors include Evotec, Gimv, European Union, Vesalius Biocapital, and BioMedPartners.